Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04600089 · ClinicalTrials.gov registry record · Phase 2

Ketamine in Patients Undergoing TEVAR Procedures Receiving NCI

A Phase 2 study of Postoperative Pain and Thoracoabdominal Aortic Aneurysm, sponsored by Sam Tyagi.

Recruiting
Registry status
Phase 2
Development phase
30
Enrollment target
1
Study location

NCT04600089 is a Phase 2 study of Postoperative Pain and Thoracoabdominal Aortic Aneurysm that is actively recruiting participants, run by Sam Tyagi. The registered enrollment target is 30 participants, below the 231-participant average among 63 other Postoperative Pain trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04600089, a Phase 2 study of Postoperative Pain and Thoracoabdominal Aortic Aneurysm, is actively recruiting participants, sponsored by Sam Tyagi.

RECRUITING
Registry status
Phase 2
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The objective of this study is to identify the opioid-sparing effects, and pain-reduction potential of low dose, sub-dissociative ketamine on patients undergoing thoracic endovascular aortic repair (TEVAR) procedures receiving naloxone continuous infusion (NCI).

Interventions

  • DRUG Ketamine
  • DRUG Saline

Study Locations (1)

Kentucky

  • University of Kentucky Medical Center - Lexington

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2020-12-08
Est. Completion 2027-08
Phase Phase 2

Sponsor

Sam Tyagi

1 total trials

What the Registry Record Tells You About NCT04600089

The ClinicalTrials.gov registry entry for NCT04600089 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 231-participant average among 63 other Postoperative Pain trials with a reported enrollment target (87% lower). The listed sponsor is Sam Tyagi, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Postoperative Pain appearing as the primary indexed condition, and to 2 interventions - of which Ketamine is the first listed.

NCT04600089 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.

Frequently Asked Questions

What is clinical trial NCT04600089 about?

NCT04600089 is a clinical study titled "Ketamine in Patients Undergoing TEVAR Procedures Receiving NCI". The objective of this study is to identify the opioid-sparing effects, and pain-reduction potential of low dose, sub-dissociative ketamine on patients undergoing thoracic endovascular aortic repair (TEVAR) procedures receiving naloxone continuous infusion (NCI).

What is the current status of trial NCT04600089?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2020-12-08. Estimated completion is 2027-08.

What conditions does trial NCT04600089 study?

This clinical trial studies the following conditions: Postoperative Pain, Thoracoabdominal Aortic Aneurysm, Descending Aortic Dissection.

What interventions are being tested in trial NCT04600089?

The interventions under investigation include: Ketamine (DRUG), Saline (DRUG).

Who is sponsoring clinical trial NCT04600089?

This trial is sponsored by Sam Tyagi, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04600089 being conducted?

This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Postoperative Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.